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Abstract: Comparison of the effect of systemic administration and transamine position on bleeding and the need for 
blood transfusion in patients undergoing coronary artery bypass surgery, goals, comparing the amount of bleeding and 
blood transfusion in 48 hours after surgery, design by random sampling by blocking, 180 patients will enter this study, 
How to do after seeking consent, 60 patients will be assigned to the systemic intervention group and 60 patients will be 
assigned to the intervention group and 60 patients will be in the control group. Entry requirements: All patients 
undergoing coronary artery bypass graft surgery for the first time. Exclusion criteria in patients with renal failure, 
anemic patients, patients with low cardiac output, patients with coagulation disorder, and intervention; patients 
undergoing anesthesia induction of 10 mg / kg of body weight within the regimen Receive a dose of 1 mg of the drug 
per kg body weight per surgical hour until the end of surgery, after the surgery. In the local group, 1 g of the transamine 
solution was dissolved in 100 ml of chloride. 0.9% at the end of the surgery in the pericardial cavity of the heart. 60 
patients will not receive the drug control group, all of the surgery will be performed by two surgeons under the same 
anesthetic and bypass procedure, the main outcome of the cerebral hemorrhage 6, 12, 24, 48 hours after surgery, and the 
rate of blood transfusion in 48 hours. From surgery. 




Introduction. Despite the recent advances in surgical techniques and post-exposure care, the amount of post-surgical 
hemorrhage remains around 600-120a0 ml, of which about 25-45% of these cases are fibrinolysis (1, 2). This is while 
the outflow of blood also exacerbates fibrinolysis (3, 4). Preventive use of fibrinolysis inhibitors (aprotinin and lysine 
analogues such as aminocaproic acid and transamine) has been common in cardiac surgery to reduce bleeding and the 
need for transfusion of blood since the 1980s (5). Currently, trancean amine is less expensive and has a higher immunity 
level than aprotinin, and also 7 to 10 times that of aminocaproic acid, the most commonly used anti-fibrinolytic drug (6-
9). This drug, while significantly reducing the concentration of plasminogen, slows down the fibrinolysis process, 
because although plasmin is still produced, it is inhibited and can not bind to fibrin (10-12). Studies also show anti-
inflammatory effects and improve platelet function in patients receiving the drug (15-15). Although systemic use of 
transamine has been effective in heart surgery and is recommended by the Association of Thoracic Surgeons and the 
Association of Cardiology Anaesthesiologists, the best way to prescribe it remains to be discussed. (16-18). 
According to studies, concerns about the complications observed following systemic administration of the drug, 
including seizure and thromboembolic complications, have increased (22-19). On the other hand, based on the natural 
characteristics of the pericardium that prevents the release of substances, topical application of various drugs in the 
pericardium cavity can increase the desired therapeutic effects of the drug without systemic absorption (1, 23). In the 
case of transamin, topical administration in the pericardial cavity to avoid systemic complications has had effective 
results in reducing bleeding (9, 16, 19, 24). Some studies have also reported the need for transfusion of blood products 
in topical use (5, 9, 19). The topical use of this drug in other cardiovascular and other therapies, including bladder 
bladder surgery, gynaecologic surgery, oral mouth, and surgeries Otolaryngeal ovary and thrombosis, as well as 
hemiartheroplasty, have been effective. (25-29). 
The aim of this study was to compare the effect of systemic and topical administration of transamineal agents on 
bleeding and the need for blood transfusion in patients undergoing elective CABG surgery on-pump. 
 
Method 
With the approval of the ethics committee of Shiraz University of Medical Sciences and the registration of the IRCT 
IRCT2013071210311N3 IRCT, this randomized, double blind randomized clinical trial study was conducted on 180 
patients with electrocardiogram Who have been undergoing CABG surgery for the first time in the two hospitals of 
Namazi and Martyr Faghihi from February to August. The primary objective of this study was to determine the amount 
of bleeding and secondary goals including the measurement of blood transfusion, mechanical ventilation, patient's 
residence in the ICU, death and thromboembolic complications (early blockage of coronary arteries, stroke, deep vein 
thrombosis, embolism, seizure), and They were compared in two ways: the administration of systemic and topical 
transamin. Exit criteria for exclusion criteria were from patients with combined / cadaveric / emergency procedures / 
haemorrhagic disorders such as hemophilia or platelet counts ≥100,000 / renal failure ≥ 1.5 cr / history of transaminase-
peritoneal allergy Cardiac Down (30EF≤) / Anemic (11HB≤) / History of antiplatelet drugs (aspirin / clopidogrel) 
within 5 days before surgery / history of heparin infusion 24 hours prior to surgery / history of oral anticoagulation 
(warfarin) and non-inflammatory drugs Non steroid anti inflammatory drugs (steroids) within 3 days before surgery. 
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Patients were randomly assigned to one of the three groups using permutation blocks. 
The first group (systemic): 60 patients entered into this group received normal 10 mg / kg 10 transamine in 20 ml of 
normal saline in 20 minutes after induction and before incision, followed by infusion of 1 mg / kg / hr The drug was 
taken as a solution in 50 ml normal saline until the end of the treatment. At the end of the surgery and before closing the 
sternum, 100 ml of normal saline was poured into the surgical area and the pericardial space. After 15 minutes, the casts 
of the tubes were removed and drainage was performed. 
 
Group II (topical): 60 patients entered this group after induction and before skin incision, similar to the systemic boluses 
and infusion group, with the difference that only normal saline was used instead of the medication. At the end of the 
surgery and before closing the sternum, 1 g of transamine was dissolved in 100 ml of normal saline in the surgical area 
and the pericardial space. After 15 minutes, the clusters of the chest tubes were removed and drainage was performed. 
Group III (control): 60 patients entered into this group received both the systemic and topical methods at similar times 
and the same values as normal saline alone. 
According to a study conducted in 1995 on various systemic doses of transamine (from 2.5 mg / kg to 40 mg / kg) (19), 
the minimum and effective dose of this drug was 10 mg / kg bolus In the next infusion, mg / kg / hr 1 was expressed, as 
in the topical method, the first result was 1 g of drug (21). These values are used as the minimum effective dose of the 
drug in two different methods of administration in this study. Pre-prepared solutions, not prescription drugs (anesthetist 
nurse and scrub nurse), were aware of the contents of the solutions, nor were the nurses of the special department aware 
of the grouping of patients. Two heart surgeons using the same surgical technique in this study have been used. 
Anesthesiologists and perfusionists from these two anesthetic management centers and CPB all patients in accordance 
with a predetermined protocol. 
Anesthesia induction was performed using midazolam (0.15 mg / kg), sufentanil (5 μg / kg), pantothenal (3 mg / kg), 
morphine (0.1 mg / kg) and fulmin (0.15 mg / kg). Propofol is also used to maintain anesthesia. Prior to CPB, 3,000 u / 
kg of heparin was prescribed and 3 minutes later ACT was investigated, the oxygenator used for CPB, Hepari coated, 
however, was added to the primer solution to ensure heurinisation of all levels and pathways of about 5000 heparins. 
The primer solution contains a serum lingerie ringer veiner. Generally, hypothermic cardioplegia is a combination of 
blood, crystalloid and anti-gradient for cardiopulmonary artery, and the LIMA (Left Internal Mammary Artery) artery 
and the saphenous vein for the treatment of coronary arteries. Eventually, in order to reverse the effect of heparin, 1 mg 
of protamine was administered per 100 ui heparin and transferred to the intensive care unit after closure of the patient's 
chest. 
All demographic characteristics of the patients, such as age, sex, BSA, history of underlying diseases (diabetes, 
hypertension, hyperlipidemia, heart attack, DVT, COPD) were collected at the time of admission. Blood and 
coagulation tests including pre-operative HB / CR / PT / PTT / INR were recorded immediately after entering ICU and 
24 hours after surgery. 
All cases were recorded and checked to ensure that the conditions were the same during operation such as duration of 
surgery, CPB duration, aortic cross-clamping time, number of casts, duration of sternum closure (from the time of 
injection of protamine to the last skin surgeries) . In ICU, the drainage of chest tubes at 6, 12, and 24 hours after 
surgery, as well as the length of stay there and the mechanical ventilation time were recorded. Transfusion of blood 
products to patients is also done according to a protocol that prescribes tuberculosis with HCT 30 and FFP in the case of 
1.5 INR in patients with active bleeding and platelet administration with platelet levels below 70,000 and continued. 
Blood is done (30). In the case of re-implantation, reexploration has been excluded from the study with a sudden 
increase in drainage of chest tubes (300 ml / hr), or the occurrence of any postoperative complications, including 
thromboembolic complications and death.  
Statistics Analysis 
All data were analyzed using R software version 3.3.1. First, Kolmogorov-Smirnov test was used to evaluate the natural 
distribution of data. In order to determine the intra-group and inter-group differences in the distribution of measured 
variables, if the data are normal, Repeated measures, ANOVA and, if not normal, Friedman test ) And kruskal-wallis 
test. Chi-square test was used to test the demographic and clinical variables in two groups. . P value <0.05 was 
considered as a significant level for all statistical analyzes. 
 
Results 
The three groups included in this study were comparable in terms of preliminary demographic data and risk factors 
(including underlying diseases) (Table 1).  
 






























0.775 66.25±11.20 66.26±11.75 67.15±10.93 Weight(kg) 
 
0.136 1.66±0.16 1.68±0.15 1.72±0.14 BSA(m²) 
 
0.265 51.01±6.68 49.21±7.66 51.27±6.66 EF(%) 
 
0.273 29(49.2) 20(35.1) 23(39) DM(%) 
 
0.853 35(59.3) 36(63.2) 38(64.4) HTN(%) 
 
0.199 31(52.5) 31(54.4) 23(39) HLP(%) 
 
0.815 9(15.3) 8(14) 11(18.6) COPD(%) 
 
0.213 12(20.3) 18(31.6) 11(18.6) MI(%) 
 
*Mean±Standard Deviation 
Abbreviations;  BSA: body surface area, EF: ejection fraction, DM: diabetes mellitus, HTN: hypertension, HLP: 
hyperlipidemia, COPD: chronic obstructive pulmonary disease, MI: myocardial infarction 
Also, the comparison of surgical parameters including the number of casts, the use of the LIMA artery, the duration of 
operation, the duration of the aortic aberration and cross-clamping, as well as the duration of sternum closure (from the 
beginning of the injection of protamine to the last skin surgeries), showed that three groups In the operating room, the 
conditions were the same and there was no significant difference between the three groups (Table 2).  















Number of Grafts 
(no) 
 
2.94±0.70∗ 2.89±0.58 2.71±0.67 0.095 
Use of LIMA  
(% used) 
 
















38.30±10.97 35.35±9.25 34.40±7.99 0.111 
*Mean±Standard Deviation    
Abbreviations;  LIMA: left intenal mammary artery, CPB: cardiopulmonary bypass. 
 
 
Measured laboratory parameters included hemoglobin, creatinine, prothrombin time, partial thromboplastin time, 
international normalized ratio. 
Before surgery, immediately after entering the ICU, and the day after operation, in Table 3, the comparison was made 
between the three groups except PTT factor (P = 0.008) and INR (P = 0.017)  
Table 3. Hematologic Measures in Time1(Pre-operative), Time2(Immediately Post-operative), Time3(Post-operative 
Day 1). 
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Abbreviation;  HB: hemoglobin, CR: creatinine,  PT: prothrombin time,  PTT: partial thrombpplastin time, 
INR:international normalized ratio. 
**( Local-Systemic p=0.002) 
***( Local-control p=0.030) ,( Local-systemic p=0.007) 
 
 
Fig 1. Pos-op Blood Loss/Time Interval 
 
At the second time of measurement, there is no significant difference between the groups .The amount of postoperative 
bleeding is shown in Fig. 1, which shows that the average drainage of the chest tubes in the first 6 hours immediately 
after surgery (which is a golden age) is between the three control groups (227.26 ± 187.16) and the systemic (207.01 ± 












results of the comparison between the groups indicated that the bleeding in the local group was lower not only 
compared to the control group (p = 0.0001), but even less than the systemic group (p = 0.002). In the follow-up 
drainage study, at 6 hours after surgery (12 hours), the mean of bleeding in the control groups (139.83 ± 122.39) and 
systemic (89.47 ± 63.20) and topical (122.88 ± 85.76) groups was statistically significant (p <0.001). p = 0.039). 
Compared with the control group (p = 0.027) and compared with the patients in the topical group (p = 0.027), they had 
less bleeding than the patients who received systemic transamine in the first 6 hours. After 12 hours of surgery, there 
was a decrease in the rate of bleeding between the groups, so that at the time (12-24 hours), the mean of bleeding in the 
control group (183.89 ± 154.37) and systemic (150.00 ± 116.49) and topical (191.52 ± 118.23) showed no significant 
difference (p = 0.106). From the second day (24-end), the mean of bleeding in the control group (133.65 ± 97.64), 
systemic (155.26 ± 161.93), and localized (91.59 ± 122.88) were the mean of the previous time, with a decrease in the 
amount of bleeding in There was no significant difference between the two intervention groups as compared to the 
control group (p = 0.669). 
The results of the study of cumulative bleeding during the first 24 hours after surgery and general bleeding (from the 
beginning to the exit of the chest tubes) indicate that the rate of bleeding in the patients receiving topical transaminazole 
has significantly decreased compared with those receiving placebo ( Respectively 0.011 p = and 0.010 p =). Also, 
although the rate of cumulative hemorrhage in patients receiving intra-erythropoietin transamine was always lower than 
that of placebo recipients, this difference was significant only at the end of the first day (p = 0.030) and not in total (p = 
0.067) . In comparison with the two intervention groups, the results indicated that the effect of topical administration of 
the drug on the reduction of cumulative bleeding was higher in the first 24 hours (p = 0.73) and in total (p = 0.47) than 
in the systemic administration, The statistical significance was not significant (Fig. 2) 
 
Fig 2. Post –op Blood Loss/24 hours and total. 
0-24:   control(median of 552.88±294.38 ), systemic(median of 446.49±257.71), local(median of 421.18±222.87 ) 
0-end: control( median of 688.98±317.18), systemic(median of 607.01±337.59f), local(median of 547.45±246.25 ) 
 
According to the results of this study, using the protocol used for blood transfusion and blood products, on average 48 
hours after coronary artery bypass graft surgery, approximately one unit per injection was given to each patient, 
although this value was in The two groups of drugs were less than the control group, but there was no significant 
difference between the two groups. No quantities of platelet products were used in any of the patients in the 3 groups of 
comparison and did not differ significantly in the consumption of FFP (Table 4).  
 












1.169±1.1* 0.80±0.8 0.89±0.8 1.41 
FFP 
 
0.84±0.3 0.52±0.2 0.84±0.4 0.88 
PLT 
 
0 0 0 - 
*Mean±Standard Deviation 























On the examination of conditions and postoperative complications such asIntubation time (hours), ICU stay (day), MI, 
CVA, DVT, Seizure, Reexploration, Mortality 
It seems that the average time of mechanical ventilation (intubation time) was lower in the two intervention groups than 
the control group, but in the end, the three groups did not have a significant difference in mechanical ventilation and 
ICU stay. It should also be noted that the most complications observed belong to the patients in the systemic group, 
resulting in a patient receiving DVT, one after Reexploration and another patient due to the death of the study.  
Among the patients in the 3 groups, only one CVA case was reported that belonged to the local group and was 
excluded, and also in the control group, a case of death, which led to the deletion of this patient from the study. No 
cases of MI and seizure have been reported among all patients (Table 5). 
Table 5. Post-operative Data and Complications 









1.28±0.6* 1.38±0.7 1.37±0.74 0.81 
Intubation time 
(hours) 
13.54±7.6 12.64±6.4 12.67±5.8 0.80 
MI 
(No of patients) 
0 0 0  
CVA 
(No of patients) 
0 0 1  
DVT 
(No of patients) 
0 1 0  
Seizure 
(No of patients) 
0 0 0  
Reexploration 
(No of patients) 
0 1 0  
Mortality 
(No of patients) 




Discussion & Conclusion 
On-pump heart surgery is associated with more coagulation disorders than other surgeries. Fibrinolysis has been 
reported as the cause of 25-45% of post-surgical hemorrhage. (2) Outward circulation also leads to a significant 
increase in fibrinolysis, which is indicated by increasing the concentration of plasmin and FDP (Fibrin degradation 
product) and These two factors have both adverse effects on platelet function (4). On the other hand, reopening of the 
chest after bleeding can be an independent and potent factor for the occurrence of unpleasant outcomes following heart 
surgery, including risk factors such as age, low BMI, non-elective patients, and more than 5 anastomosis numbers. (31, 
32). As a result of these factors, the rate of blood transfusion in the heart surgery is 30% to 70% more than other 
surgeries, which itself has many effects. (23, 33, 34) Previous studies in the evaluation of intra-regimen use of 
transamine Postoperative bleeding and need for blood transfusions. 
Also, some investigations have investigated the effect of topical transamine in the surgical field on the rate of 
hemorrhage and hemostasis, as well as the avoidance of systemic thromboembolic complications. According to our 
study, systemic administration of 10 mg / kg of transamine medication and infusion of 1 mg / kg / hr to the end of 
operation in elective patients undergoing coronary artery bypass grafting is effective in reducing postoperative bleeding, 
especially at a time interval of 12-12 hours. Horrow, in its protocol, expresses at least 10 mg / kg of systemic 
transaminase systemic effects in heart surgery and infusion of 1 mg / kg / hr to 12 hours postoperatively. According to 
the results of this study, these values of the drug significantly reduced the amount of bleeding Within 12 hours of 
cardiac surgery, the systemic dose in our study is also derived from this study and our results confirm this. (35). 
 
It should be noted that when comparing higher doses of transamine (20, 50, and 100 mg / kg), there was no difference in 
the amount of bleeding during operation and 24 hours after surgery (12, 36). Therefore, it can be said that higher doses 
do not necessarily have a greater effect on the reduction of bleeding. It should be noted that the differences in the type 
of operations and the removal or inclusion of high risk patients may be influenced by the systemic administration of the 
drug, while the pharmacokinetic effects of intravenous administration of this drug are also strongly influenced by CPB 
(16, 37) Also, our findings suggest that the rate of bleeding in patients receiving 1 g of topical transaminazole in the 
pericardial cavity during the first 6 hours after surgery was not only comparable to placebo recipients, but even 
compared to patients receiving systemic transamine Also, it has fallen further. This rapid reduction in the amount of 
early post-op infection has led to a significantly lower left ventricular hemorrhage rate, even though there is less effect 
on subsequent periods of time. According to these results and the study of De Bonis, which showed that no drug was 
absorbed into the blood by laboratory tests of blood, it can be argued that the drug in the pericardium has an anti-
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fibrinolytic effect and localized fibrinolysis control can also reduce the rate of postoperative drainage Effectively reduce 
(9). 
On the other hand, regarding the role of CPB, although the fibrinolysis exacerbation is a complication, the results show 
that the use of 1 g of topical transaminazole in CABG patients by off-pump with a significant reduction in bleeding 
during the first 24 hours after surgery (24). Thus, it can be argued that obtaining similar results in the local application 
of the same values of transamine in CABG patients both on-pump and off-pump can confirm the greater role of 
fibrinolysis activity in the pericardium compared to systemic fibrinolysis. The results of topical use of transamine in our 
study and other studies indicate that not only in CABG but also in other cardiac injuries, this drug can be effective in 
reducing postoperative bleeding, as well as in topical administration of transamine to aprotinin Is effective in reducing 
the amount of bleeding after heart surgery and is economically feasible (1, 38) in clinical interventions recently 
evaluated by the effect of topical transaminomal lacquer versus pericardial lavage with normal saline , There was no 
difference in the rate of bleeding 12 hours after the operation (18). 
 
In explaining the results, it can be noted that all patients in the study received 2 grams of systemic transamin (1 gram 
before skin incision and 1 gram after CPB), while in contrast to our protocol, which was administered topically for 15 
minutes In the space of the pericardium and then suctioned, in this study, topical use of the drug was only effective for 
one minute and was used only for lavage. Therefore, our recommendation for topical use of transamine in the 
pericardium is to give at least 15 minutes to the medication. In our study, for the first time, two systemic and topical 
administrations of transamine (with a minimum effective dose) were compared in cardiac surgery. According to our 
results, the study of the amount of bleeding by time intervals shows that in the first 6 hours after surgery, the topical 
effect of the drug and in the 6 hours after the operation had a systemic effect of the drug on the opposite method, and 
the maximum effect of both methods of administration of the drug up to 24 The hour will be after the operation. 
Perhaps the cause of this difference is related to the continuation of systemic systemic infusion until the end of the 
operation and the administration of topical doses at the end of the procedure, as well as the short acting effect of the 
drug due to lack of absorption in the systemic circulation. 
In order to achieve the second goal of this study on the rate of blood transfusion, we should say that according to our 
results and other studies, the systemic dose of transamine has no role in the rate of blood transfusion and blood 
products. In the event of higher systemic doses, the results are also variable (contradictory). (17, 36). Although the 
larger sample size in the studies seems to be relevant to the study of this factor (39). Unlike De Bonis, who for the first 
time reported a decrease in blood transfusion requirements for topical use of 1 g of transamine in cardiac surgery (9), 
Our study results suggest that although the average number of injected blood units in these patients has decreased, this 
effect is not significant. This difference in the results of the effect of transamine on blood transfusion can have many 
causes, including the difference in blood transfusion protocols and even the lack of compliance by the specialist staff, 
the initial hematological status of patients, as well as the difference in sample size and elimination Or the entry of 
overweight patients will be effective in the study.  
In addition, it should be noted that although drainage of chest tubes is a risk factor for blood transfusion, studies show 
that it is not necessarily a high rate of drainage predicting blood transfusion (29). It should also be noted that, according 
to our study, the mechanical ventilation and residence time of patients in the icu section are not affected by local and 
systemic transamin injection. Since the average duration of sternum closure (from the beginning of protamine to the 
closure of sternum skin) in both groups of medication has been less controlled, it can be said that this time can be an 
important predictive factor in the estimation of the bleeding status of patients after cardiac surgery. Despite concerns 
about the risk of developing tamponade over topical use of medication, there is no evidence that the administration of 
transamin in the pericardium can increase the risk of developing tamponade.  
The occurrence of DVT in the patient receiving systemic administration of the drug (with a minimum dose) suggests 
that the complications of thromboembolic treatment should be avoided. Disturbing results The recent study of systemic 
systemic doses of transamine (mg / kg) (24) suggests a doubling in the incidence of seizure and mortality in these 
patients. However, the mechanical ventilation and residence time in ICU has also decreased in these patients (20). 
However, since this study was conducted in all types of cardiac surgeries, it should be noted that differences in surgical 
techniques, high risk of embolic events, and exacerbation of inflammatory response due to prolonged CPB in 
complicated and open heart surgery have had an impact on these outcomes. They are What is always recommended is 
that the benefits of systemic administration of anti-fibrinolytic drugs should be weighed against its side effects. In 
general, topical use of 1 g of transamine medication as well as systemic use of 10 mg / kg and infusion of 1 mg / kg / hr 
up to the end of the operation reduces bleeding to 24 hours following CPB coronary artery bypass graft surgery. Topical 
use of 1 g of transamine medication may be effective in reducing esrly post-op period bleeding without complications 
such as tamponade, renal dysfunction and thromboembolic events. Also, although both blood pressure (P <0.001) was 
reduced with both drug administration methods, it was not statistically significant. Since this comparison between the 
two methods of prescribing transaminase has not been studied in any cardiac surgery study, more studies are needed 
with a larger sample size in order to achieve conclusive results. 
 
Limitations 
The use of cardiac surgeons with a completely similar technique and the collaboration of anesthesiologists, perfusionists 
and ICU nurses in complying with the protocols has been one of the limitations of this study. Also, the inability to 
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check the blood of patients receiving topical transamineal medication was not allowed to comment on the absorption or 
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